news
-
31 August 2021Sequana Medical appoints Jackie Fielding, former Medtronic VP, to its Board of Directors
Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that it has appointed Jackie Fielding, a former Vice President of Medtronic with more than 30 years of experience in the healthcare industry, as an independent Non-Executive Director of the Company, effective as of 1 September 2021 upon approval by the Board of Directors. She replaces Jason Hannon who is stepping down from the Board of Directors due to his return to California. The appointment of Ms. Fielding will be submitted for confirmation to the Company’s next General Meeting of Shareholders.
“We are delighted to welcome Jackie Fielding to our Board of Directors,” said Pierre Chauvineau, Chairman of the Board at Sequana Medical. “Her extensive experience in the development and commercialisation of innovative medical devices and as a board member in both the corporate and public sectors will be invaluable as we progress the development of alfapump® and alfapump DSR®, seeking to transform the care of liver disease and heart failure. We thank Jason for his tremendous contributions and wish him well with his return to California.”
Ms. Fielding spent 28 years with Medtronic, most recently as Vice President UK / Ireland, where she was responsible for more than 700 staff and revenue of approximately $750 million. She held a number of external posts alongside her role at Medtronic, including Chair of the BCIA (British Cardiovascular Intervention Association) and council member of the BCIS (British Cardiovascular Intervention Society).
In 2010, she was elected to the Board of Directors of ABHI (Association of British HealthTech Industries) and in 2015 was appointed Vice Chair. Ms. Fielding has worked with the UK’s NHS (National Health Service) Clinical Entrepreneur programme and was a member of the Ministerial Medical Technology Strategy Group. She is Non-Executive Director on the Boards of UK’s NICE (National Institute for Health and Care Excellence), 3D Life Prints and Northumbria Primary Care, of which she is also Chair.
“I look forward to working with the Sequana Medical Board of Directors and Management Team,” said Ms. Fielding. “I believe that their alfapump and Direct Sodium Removal technologies have the potential to transform the care of diuretic-resistant fluid overload, and look forward to contributing my experience and knowledge to the success of the Company.”
Related
Sequana Medical announces first patient enrolled in SAHARA DESERT
Sequana Medical announces 2020 Full Year Results and 2021 Outlook
Sequana Medical announces granting of key alfapump DSR® patents in U.S. and Europe
Sequana Medical announces H1 2020 results and provides business update
Sequana Medical announces €7.3 million debt financing and provides clinical update
Sequana Medical announces 2019 Full Year Results and 2020 Outlook
Sequana Medical announces new share capital amount and new number of shares
Sequana Medical announces 2019 Half Year Results and Year-to-date Business Update
Sequana Medical appoints leading experts as Heart Failure Scientific Advisors
Sequana Medical to host webcast on 27 May 2019
Sequana Medical announces 2018 Full Year Results and 2019 Outlook
Sequana Medical raises €27.5 million in successful Initial Public Offering
Sequana Medical Announces Publication of Results of Multicentre Randomized Controlled Study
Sequana Medical Announces Results of the MOSAIC trial data presented at 2017 AASLD
Sequana Medical Announces Sudden Passing of Founder, President & CEO
Ian Crosbie Joins Sequana Medical as Chief Financial Officer
Sequana Medical has been selected as a finalist for the 2012 MEDTEC EMDT Innovation Awards
Sequana Medical receives CE Mark Approval for the ALFApumpTM System and adds key executive to team
NovaShunt announces the launch of its new corporate identity: Sequana Medical